Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Non Operating Income (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Non Operating Income for 7 consecutive years, with $247000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 112.65% to $247000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.2 million through Dec 2025, up 241.27% year-over-year, with the annual reading at $215000.0 for FY2025, 105.48% up from the prior year.
  • Non Operating Income hit $247000.0 in Q4 2025 for Allogene Therapeutics, down from $3.5 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $5.5 million in Q3 2024 to a low of -$19.0 million in Q4 2023.
  • Historically, Non Operating Income has averaged -$1.2 million across 5 years, with a median of -$279500.0 in 2021.
  • Biggest five-year swings in Non Operating Income: crashed 4050.54% in 2022 and later soared 687.51% in 2025.
  • Year by year, Non Operating Income stood at -$1.6 million in 2021, then crashed by 235.97% to -$5.4 million in 2022, then plummeted by 248.44% to -$19.0 million in 2023, then surged by 89.71% to -$2.0 million in 2024, then skyrocketed by 112.65% to $247000.0 in 2025.
  • Business Quant data shows Non Operating Income for ALLO at $247000.0 in Q4 2025, $3.5 million in Q3 2025, and -$43000.0 in Q2 2025.